Algernon Logo 1.png
Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant
August 11, 2021 07:00 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
LIXTE.jpg
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer
June 02, 2021 09:35 ET | Lixte Biotechnology Holdings, Inc.
Extensive preclinical data shows LB-100 increases the effectiveness of chemotherapy in animal modelsDue to the aggressive progression of small cell lung cancer, it is possible that therapeutic benefit...
LIXTE.jpg
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer
January 19, 2021 09:35 ET | Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...
Hillstream Biopharma logo, 06.17.2017.png
Hillstream BioPharma Granted Orphan Drug Designation for HSB-1216 (QUATRAMER Salinomycin) for Treatment of Small Cell Lung Cancer (SCLC)
January 06, 2020 08:00 ET | Hillstream BioPharma, Inc.
Positive pre-clinical data with an emerging validated mechanism of action, Ferroptosis HSB-1216 is a novel therapeutic using the QUATRAMER formulation of a potent anti-Ferroptotic compounds,...
Hillstream Biopharma logo, 06.17.2017.png
Hillstream BioPharma Announces Kwok-Kin Wong, MD, PhD as New Member to Scientific Advisory Board
November 19, 2019 07:00 ET | Hillstream BioPharma, Inc.
CHESTER, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (“Hillstream”) today announced the addition of clinician-scientist Kwok-Kin Wong, MD, PhD to Hillstream’s Scientific...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 PINNACLE Clinical Trial of Tarextumab in Small Cell Lung Cancer
August 30, 2016 08:00 ET | OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...